Horizon Therapeutics plc announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive officer. Shao-Lee Lin, M.D., Ph.D., executive vice president, research and development and chief scientific officer is no longer with the Company and a search will be initiated in the near-term for her replacement.